<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002599</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000063834</org_study_id>
    <secondary_id>MRC-LEUK-MYEL-VII</secondary_id>
    <secondary_id>EU-94030</secondary_id>
    <nct_id>NCT00002599</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy and Interferon Alfa With or Without Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloma</brief_title>
  <official_title>MYELOMA VII MEDICAL RESEARCH COUNCIL WORKING PARTY ON LEUKEMIA IN ADULTS: MYELOMATOSIS THERAPY TRIAL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical Research Council</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die. Combining bone marrow or peripheral stem cell transplantation with
      chemotherapy may allow the doctor to give higher doses of chemotherapy drugs and kill more
      cancer cells. Interferon alfa may interfere with the growth of cancer cells. It is not yet
      known whether a more intensive chemotherapy regimen plus stem cell or bone marrow transplant
      is more effective than standard chemotherapy in treating patients with myeloma.

      PURPOSE: Randomized phase III trial to compare the effectiveness of two different regimens of
      combination chemotherapy plus interferon alfa with or without high dose melphalan or bone
      marrow or peripheral stem cell transplantation in treating patients with previously untreated
      myeloma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Compare survival of patients under age 65 with myeloma treated with standard
      ABCM (doxorubicin, carmustine, cyclophosphamide, melphalan) vs. intensive C-VAMP
      (cyclophosphamide, vincristine, doxorubicin, methylprednisolone) followed by high-dose
      melphalan (with or without total-body irradiation) with bone marrow and peripheral blood stem
      cell support, both with IFN-A maintenance. II. Compare the toxicity profiles of the 2
      treatment arms. III. Compare the 2 treatment arms with respect to quality of life and health
      economics issues. IV. Investigate cellular changes by means of linked morphology, phenotype,
      and cytogenetics studies before and after treatment and at relapse.

      OUTLINE: Randomized study. The following acronyms are used: ABM Autologous Bone Marrow BCNU
      Carmustine, NSC-409962 CTX Cyclophosphamide, NSC-26271 DOX Doxorubicin, NSC-123127 G-CSF
      Granulocyte Colony Stimulating Factor (Amgen), NSC-614629 GM-CSF Granulocyte-Macrophage
      Colony Stimulating Factor (source not specified) IFN-A Interferon alpha (Hoffmann-La Roche),
      NSC-367982 L-PAM Melphalan, NSC-8806 MePRDL Methylprednisolone, NSC-19987 PBSC Peripheral
      Blood Stem Cells PRED Prednisone, NSC-10023 TBI Total-Body Irradiation VCR Vincristine,
      NSC-67574 ARM I. Induction: 4-Drug Combination Chemotherapy or, as indicated, 2-Drug
      Combination Chemotherapy. ABCM: DOX; BCNU; CTX; L-PAM; or, if pretreatment ANC and platelets
      are less than 1,300 and 75,000, CTX; PRED. Maintenance: Biological Response Modifier Therapy.
      IFN-A. ARM II. Induction: 4-Drug Combination Chemotherapy followed by Hematopoietic
      Stimulation. C-VAMP: DOX; VCR; MePRDL; CTX; followed by CTX; G-CSF or GM-CSF. Consolidation:
      3-Drug Combination Chemoablation with or without Radioablation followed by Hematopoietic
      Rescue. CTX; L-PAM; MePRDL; with or without TBI using megavoltage equipment (linear
      accelerator preferred); followed by ABM and/or PBSC. Maintenance: Biological Response
      Modifier Therapy. IFN-A.

      PROJECTED ACCRUAL: 750 patients will be accrued.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>September 1994</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">750</enrollment>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant interferon alfa</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>sargramostim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carmustine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methylprednisolone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>low-LET cobalt-60 gamma ray therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>low-LET photon therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Definite myeloma requiring chemotherapy and fulfilling at least 2
        of the following criteria: Neoplastic plasma cell infiltrate and/or microplasmacytomas on
        bone marrow aspiration and/or trephine Paraprotein in blood and/or urine Definite lytic
        bone lesions (not simply osteoporosis) No equivocal myeloma (such patients should be
        registered with the Clinical Trial Service Unit, Oxford)

        PATIENT CHARACTERISTICS: Age: Under 65 Performance status: Not specified Hematopoietic:
        (following rehydration and treatment for infection, if necessary) ANC at least 1,000
        Platelets at least 50,000 Hepatic: Not specified Renal: Renal insufficiency does not
        necessarily exclude (dose reduction may be applicable) Cardiovascular: No severe cardiac
        disease Past history of ischemic heart disease may exclude at the discretion of the
        investigator Pulmonary: No severe respiratory illness Other: Ability to tolerate at least 3
        liters/day of fluid No life-threatening disease unrelated to myeloma Prior or concurrent
        psychiatric disorder may exclude at the discretion of the investigator No prior malignancy
        except: Nonmelanomatous skin tumors In situ carcinomas

        PRIOR CONCURRENT THERAPY: No prior therapy other than minimal local radiotherapy for relief
        of bone pain
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J. A. Child, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Leeds General Infirmary</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Leeds Teaching Hospital Trust</name>
      <address>
        <city>Leeds</city>
        <state>England</state>
        <zip>LS1 3EX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>May 20, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2004</study_first_posted>
  <last_update_submitted>December 18, 2013</last_update_submitted>
  <last_update_submitted_qc>December 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2013</last_update_posted>
  <keyword>stage I multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Carmustine</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

